BGLC
BioNexus Gene Lab Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · MY
$1.41
−4.08%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-37.7%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Tan Lee Su-Leng · director, 10 percent owner, officer: Chief Executive Officer | A-Award | 338,709 | $1.55 |
| Aug 14, 2026 | Yap Chee Keong · director | A-Award | 32,258 | $1.55 |
| Aug 14, 2026 | Bin Abdul Hamid Muhammad Azrul · director | A-Award | 32,258 | $1.55 |
| Aug 14, 2026 | Chong Set Fui · officer: Chief Financial Officer | A-Award | 96,774 | $1.55 |
| Aug 14, 2026 | Low Jook Yuen · director | A-Award | 16,129 | $1.55 |
Institutional positioning
13F filings over the trailing two quarters
New 2Increased 0Reduced 0Sold out 2
| Filer | Action | Shares | Filed |
|---|---|---|---|
| UBS GROUP AG | New Position | 231 | May 5, 2026 |
| WELLS FARGO & COMPANY/MN | New Position | 1 | Jul 8, 2026 |
| WELLS FARGO & COMPANY/MN | Sold Out | 0 | Jul 8, 2026 |
| UBS Group AG | Sold Out | 0 | May 5, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 14, 2026